Business Context and Reporting Period
This Form 8-K is a current report filed by Bionexus Gene Lab Corp. (BGLC) on May 8, 2024. The Company is incorporated in Wyoming and its common stock trades on the Nasdaq Capital Market. The filing addresses a specific regulatory matter regarding the Company's continued listing status on Nasdaq.
Key Financial Metrics
This filing is a notice of a listing deficiency and does not contain financial statements. Consequently, the document provides no data regarding revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metric.
Material Changes and Listing Status
- Deficiency: The Company failed to comply with Nasdaq Continued Listing Rule 5550(a)(2) due to a closing bid price below $1.00 per share for 30 consecutive business days, a condition first notified on November 6, 2023.
- Initial Compliance Period: The Company was granted an initial 180-day period to regain compliance, which expired on May 6, 2024.
- Extension Granted: On May 8, 2024, Nasdaq granted an additional 180-calendar day extension (the "Additional Period") until November 4, 2024.
- Proposed Cure: The Company intends to cure the deficiency during this extension, potentially by effecting a reverse stock split if necessary.
Outlook, Risks, and Contingencies
Compliance Requirement: To regain compliance during the Additional Period, the Company's closing bid price must reach at least $1.00 for a minimum of ten consecutive business days.
Delisting Risk: If the Company fails to cure the bid price deficiency by November 4, 2024, Nasdaq will provide written notice of delisting. The Company retains the right to request a hearing before the Nasdaq Hearings Panel, which would stay delisting actions pending the hearing outcome.
Management Commentary: Management states it will use all reasonable efforts to achieve compliance but explicitly notes there can be no assurance that the Company will regain compliance with Rule 5550(a)(2) or other listing criteria.
Investor Verification Checklist
- Verify the current closing bid price of BGLC stock to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other capital structure changes intended to raise the share price.
- Track the stock price performance over the next 10 consecutive business days to determine if the immediate compliance trigger is met.
- Review future filings for any updates on the delisting timeline or hearing requests if the November 4, 2024 deadline is approached without compliance.